New Delhi: A study by the Indian Council of Medical Research- National Institute of Virology (ICMR-NIV) has found that the indigenously developed Covaxin by Bharat Biotech is effective against Delta (B.1.617.2) and Beta (B.1.351) variants of SARS-CoV-2, which causes COVID-19.
The research paper, titled – ‘Neutralisation against B.1.351 and B.1.617.2 with sera of Covid-19 recovered cases and vaccinees of BBV152’ – authored by ICMR, ICMR-NIV, and Bharat Biotech is yet to be peer-reviewed.
The study, conducted to evaluate the neutralization potential of Covaxin, demonstrated that despite a 2.7- fold reduction in neutralization titers with sera of COVID-19 recovered cases (3.3-fold and 4.6-fold) and BBV152 vaccinees (3.0 and 2.7-fold) against B.1.351 and B.1.617.2 respectively, its neutralization potential is well established and demonstrated a positive response against the two variants. The neutralizing title refers to the level of antibodies created by the vaccine.
Scientists at the Indian Council of Medical Research- National Institute of Virology (NIV) evaluated the neutralization potential of sera collected from 20 recovered COVID-19 patients and 17 people who had received the Covaxin dose number 2,28 days earlier.
Covaxin, which was developed by Hyderabad-based vaccine maker Bharat Biotech in association with ICMR, is one of the three vaccines presently being administered in the country along with Serum Institute of India’s Covishield and Russia’s Sputnik V.
The seropositivity rates and the median anti-spike antibody titer are significantly higher in Astra Zeneca’s Covishield as compared to Bharat Biotech’s Covaxin, as per a study conducted by Coronavirus Vaccine-induced Antibody Titre (COVAT).
The study by COVAT was conducted on 515 health workers in India who have received both doses of either of the two COVID vaccines- Covaxin and Covishield. Out of the total number, 95.0 percent showed seropositivity after two doses of both vaccines.